BioMimetic Therapeutics, Inc. is a late-stage biopharmaceutical company focused on the development and commercialization of innovative protein-based products for the treatment of musculoskeletal and orthopedic disorders including bone, cartilage, tendon and ligament injuries - the most frequent cause of disability worldwide. The company's lead technologies are for the healing and restoration of bone and other tissues. Its lead products are based on recombinant human platelet-derived growth factor BB (rhPDGF-BB). As the foundation for its technology, BioMimetic has licensed approximately 30 issued patents from Harvard University and ZymoGenetics, Inc.. These patents provide some of the broadest coverage available in the pharmaceutical industry for the use of proteins termed "tissue growth factors" - growth factors believed to be critically important to the natural wound healing process for almost all tissues in the body, including bone, cartilage, skin and nerves. By formulating these potent molecules in the appropriate, tissue specific matrix it is possible to stimulate the regeneration of many tissues. BioMimetic was aquired by Wright Medical Group Inc. (orthopedics) in March 2013.
